We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Treatment Option for Restenosis

By HospiMedica staff writers
Posted on 27 Nov 2000
An investigational drug called tranilast shows promise in preventing restenosis by interfering with the proliferation and migration of smooth muscle cells in the arterial wall and by inhibiting the release of chemical mediators of inflammation. More...
Data from an animal study presented at the European Society of Cardiology in Amsterdam showed support for the antiproliferative effect of the drug.

A massive international trial called PRESTO (Prevention of Restenosis with Tranilast and its Outcomes) enrolling 11,500 patients at more than 450 medical centers in 17 countries is seeking to determine if tranilast can reduce the major adverse events associated with restenosis, such as death, heart attack, and the need for revascularization. All trial patients have completed the treatment phase of the trial. Followup evaluation will continue for another six months. Some patients are being evaluated by angiography while others are being evaluated by intravascular ultrasound.

Tranilast is being developed by SmithKline Beecham (SB, Philadelphia, PA, USA) under license from Kissei Pharmaceutical Co., Ltd. (Tokyo, Japan). "The size and scope of the PRESTO reflects our specific commitment to providing a new treatment option to prevent restenosis and our overall commitment to making significant contributions to the field of cardiology,” said Neil Shusterman, M.D., vice president and director of the cardiovascular therapeutic unit at SB.




Related Links:
SmithKline Beecham

New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Blood Pressure Monitor
Cuff Blood Pressure Monitor
New
Tourniquet System
heidi– mein Tourniquet
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Allevion Medical receives FDA Clearance for Vantage, introducing a fully disposable approach to minimally invasive spinal decompression (photo courtesy of Allevion Medical)

Single-Use System Enables Minimally Invasive Decompression for Lumbar Spinal Stenosis

Lumbar spinal stenosis is frequently driven by hypertrophic bone that narrows the canal and produces pain. Conventional decompression often relies on larger incisions and bulky retractors, adding time,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.